This report is the second study conducted by Charles River Associates on the role and impact of Health Technology Assessment (HTA) worldwide. The report assesses the performance of the HTA process in 16 countries with mature or developing HTA systems according to international best practice principles.
To read the report, please click below.
Disparities in screening and diagnosis for triple negative breast cancer
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...